Abstract
With conventional induction chemotherapy 60 to 70% of adult patients with acute myelogenous leukemia (AML) achieve complete remission (CR) [1]. Chemotherapeutic protocols for induction treatment mainly consist of cytosine arabinoside (Ara-C) combined with daunorubicin. To improve the induction remission rate new agents with higher anti-leukemic activity can be administered. Idarubicin (4-demethoxydaunorubicin) is an anthracycline that lacks the methoxyl group in position 4 of the aglycon of daunorubicin. Additionally, alternate regimens with non-cross-resistant cytostatic drugs can be applied in the early phase of induction treatment [2J. A novel approach is the use ofrhGMCSF to recruit leukemic blast cells into the mitotic cycle in order to render them susceptible to S-phase specific drugs such as Ara-C [3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Büchner T, Hiddemann W (1990) Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy. Blut 60: 61
Ho AD, Brado B, Haas R, Hunstein W (1991) Etoposide in acute leukemia. Past experience and future perspective. Cancer 67 (Suppl 1): 281–284
Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber C, Haas O, Vieder L (1991) Recombinant human granulocyte- macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77: 700–711
Haas R, Schneeweiβ A, Brado B, Witt B, Hunstein W, Del Valle F. Goebel M, Ho AD (1991) Induction therapy for acute myelogenous leukemia (AML) with Idarubicin/Cytosine Arabinoside and Mitoxantrone/Etoposide in “response adapted sequence”. In: Hiddemann W, Büchner Th (eds) Acute Leukemias, Pharmacokinetics and Management of Relapsed and Refractory Disease. Springer Verlag, Vol. 34, pp 439–444
Onetto-Pothier N, Aumont N, Haman A, Bigras C, Wong GG, Clark SC, DeLean A, Hoang T (1990) Characterization of granulocyte-macrophage colony stimulating factor receptor on the blast cells of acute myeloblastic leukemia. Blood 75: 59–66
Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Reich L, Mayer K, Keefe D, Trainor K, Schluger A, Penenberg D, Raymond V, O’Reilly R, Jhanwar S, Young C, Clarkson B (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77: 1666–1674
Wiernik PH, Banks PLC, Case Jr DC, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB (1992) Cytarabine Plus Idarubicin or Daunorubicin as Induction and Consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79: 313–319
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Haas, R. et al. (1994). Idarubicin/Cytosine Arabinoside and Mitoxantrone/Etoposide with rhGM-CSF Priming for De Novo Acute Myelogenous Leukemia. In: Büchner, T., Hiddemann, W., Wörmann, B., Schellong, G., Ritter, J. (eds) Acute Leukemias IV. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 36. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78350-0_103
Download citation
DOI: https://doi.org/10.1007/978-3-642-78350-0_103
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78352-4
Online ISBN: 978-3-642-78350-0
eBook Packages: Springer Book Archive